Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX) Short Interest Down 52.1% in June

Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX – Get Free Report) was the recipient of a significant decline in short interest in the month of June. As of June 15th, there was short interest totaling 3,994 shares, a decline of 52.1% from the May 31st total of 8,343 shares. Based on an average trading volume of 48,201 shares, the days-to-cover ratio is currently 0.1 days. Currently, 0.8% of the shares of the company are short sold.

Eloxx Pharmaceuticals Stock Up 7.4%

Shares of NASDAQ ELOX traded up $0.88 during midday trading on Tuesday, hitting $12.81. 21,924 shares of the stock traded hands, compared to its average volume of 15,003. The stock has a market capitalization of $8.84 million, a price-to-earnings ratio of -0.84 and a beta of -1,932.88. Eloxx Pharmaceuticals has a one year low of $11.45 and a one year high of $17.50. The stock has a 50-day moving average price of $18.55.

Get Eloxx Pharmaceuticals alerts:

Eloxx Pharmaceuticals Company Profile

(Get Free Report)

Eloxx Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. It engaged in developing novel small molecule medicines to treat many rare and ultra-rare genetic diseases caused by nonsense mutations. The company’s lead product candidate consists ELX-02, is an optimized aminoglycoside designed to restore full-length functional proteins. It operates primarily in Waltham, MA and Rehovot, Israel. Eloxx Pharmaceuticals Inc, formerly known as Sevion Therapeutics Inc, is based in WALTHAM, United States.

Read More

• Five stocks we like better than Eloxx Pharmaceuticals
• Best Buy’s Turnaround Is Gaining Traction, But Wall Street Still Needs Proof
• AI Fears Hit Nebius Stock, But Has the Growth Thesis Changed?
• These 3 Dividend Stocks Could Boost Your Income This July
• Rocket Lab Defies Gravity With $8B Buyout

Receive News & Ratings for Eloxx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eloxx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.